Chinese Journal of Stroke ›› 2018, Vol. 13 ›› Issue (12): 1277-1281.DOI: 10.3969/j.issn.1673-5765.2018.12.009
Previous Articles Next Articles
Received:
2018-10-24
Online:
2018-12-20
Published:
2018-12-20
张建平,李亚峰,郭庚
通讯作者:
郭庚 guogeng973@163.com
基金资助:
国家自然科学基金(81201991)
中国博士后科学基金(2015M571068,2016T90115)
北京博士后工作经费资助项目(2015ZZ56)
山西省高等学校创新人才支持计划(晋教科[2013]8号)
ZHANG Jian-Ping, LI Ya-Feng, GUO Geng. The Effects of Lysophosphatidic Acid in Atherosclerotic Lesion[J]. Chinese Journal of Stroke, 2018, 13(12): 1277-1281.
张建平, 李亚峰, 郭庚. 溶血磷脂酸在动脉粥样硬化病变中的作用[J]. 中国卒中杂志, 2018, 13(12): 1277-1281.
[1] SIESS W,ZANGL K J,ESSLER M,et al.Lysophosphatidic acid mediates the rapid activationof platelets and endothelial cells by mildly oxidizedlow density lipoprotein and accumulates in humanatherosclerotic lesions[J]. Proc Natl Acad Sci USA,1999,96(12):6931-6936.[2] CUI M Z. Lysophosphatidic acid effects onatherosclerosis and thrombosis[J]. Clin Lipidol,2011,6(4):413-426.[3] CHUN J,HLA T,LYNCH K R,et al. InternationalUnion of Basic and Clinical Pharmacology. LXXVIII.Lysophospholipid receptor nomenclature[J].Pharmacol Rev,2010,62(4):579-587.[4] TOKUMURA A,MAJIMA E,KARIYA Y,et al.Identification of human plasma lysophospholipaseD,a lysophosphatidic acid-producing enzyme,asautotaxin,a multifunctional phosphodiesterase[J]. JBiol Chem,2002,277(42):39 436-39 442.[5] GIERSE J,THORARENSEN A,BELTEY K,et al.A novel autotaxin inhibitor reduces lysophosphatidicacid levels in plasma and the site of inflammation[J].J Pharmacol Exp Ther,2010,334(1):310-317.[6] FOURCADE O,SIMON M F,VIODÉ C,et al.Secretory phospholipase A2 generates the novellipid mediator lysophosphatidic acid in membranemicrovesicles shed from activated cells[J]. Cell,1995,80(6):919-927.[7] SONODA H,AOKI J,HIRAMATSU T,et al. Anovel phosphatidic acid-selective phospholipase A1that produces lysophosphatidic acid[J]. J Biol Chem,2002,277(37):34 254-34 263.[8] NAVAB M,CHATTOPADHYAY A,HOUGHG,et al. Source and role of intestinally derivedlysophosphatidic acid in dyslipidemia andatherosclerosis[J]. J Lipid Res,2015,56(4):871-887.[9] AKHTAR S,HARTMANN P,KARSHOVSKAE,et al. Endothelial Hypoxia-Inducible Factor-1αPromotes Atherosclerosis and Monocyte Recruitmentby Upregulating MicroRNA-19a[J]. Hypertension,2015,66(6):1220-1226.[10] LI Y F,LI R S,SAMUEL S B,et al.Lysophospholipids and their G protein-coupledreceptors in atherosclerosis[J]. Front Biosci(Landmark Ed),2016,21(1):70-88.[11] SMYTH S S,MUELLER P,YANG F,et al. Arguingthe case for the autotaxin-lysophosphatidic acidlipidphosphate phosphatase 3-signaling nexus in thedevelopment and complications of atherosclerosis[J].Arterioscler Thromb Vasc Biol,2014,34(3):479-486.[12] VAN NIEUW AMERONGEN G P,VERMEER MA,VAN HINSBERGH V W. Role of RhoA and Rhokinase in lysophosphatidic acid-induced endothelialbarrier dysfunction[J/OL]. Arterioscler ThrombVasc Biol,2000,20(12):E127-E133. https://www.ahajournals.org/doi/abs/10.1161/01.atv.20.12.e127.[13] BUSNELLI M,MANZINI S,PAROLINIC,et al. Lipid phosphate phosphatase 3 invascular pathophysiology[J/OL]. Atherosclerosis,2018,271:156-165. https://doi.org/10.1016/j.atherosclerosis.2018.02.025.[14] WU C,HUANG R T,KUO C H,et al.Mechanosensitive PPAP2B Regulates EndothelialResponses to Atherorelevant HemodynamicForces[J/OL]. Circ Res,2015,117(4):e41-e53.https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.117.306457.[15] TOUAT-HAMICI Z,WEIDMANN H,BLUM Y,etal. Role of lipid phosphate phosphatase 3 in humanaortic endothelial cell function[J]. Cardiovasc Res,2016,112(3):702-713.[16] ALDI S,MATIC L P,HAMM G,et al. IntegratedHuman evaluation of the lysophosphatidicacid pathway as a novel therapeutic target inatherosclerosis[J/OL]. Mol Ther Methods ClinDev,2018,10:17-28. https://doi.org/10.1016/j.omtm.2018.05.003.[17] SCHOBER A,SIESS W. Lysophosphatidic acid inatherosclerotic diseases[J]. Br J Pharmacol,2012,167(3):465-482.[18] HAYASHI K,TAKAHASHI M,NISHIDA W,et al.Phenotypic modulation of vascular smooth musclecells induced by unsaturated lysophosphatidicacids[J]. Circ Res,2001,89(3):251-258.[19] WU D D,ZHANG F,HAO F,et al. Matricellularprotein Cyr61 bridges lysophosphatidic acid andintegrin pathways leading to cell migration[J]. J Biol Chem,2014,289(9):5774-5783.[20] HAO F,ZHANG F,WU D D,et al.Lysophosphatidic acid-induced vascular neointimalformation in mouse carotid arteries is mediatedby the matricellular protein CCN1/Cyr61[J]. Am JPhysiol Cell Physiol,2016,311(6):975-984.[21] HAO F,TAN M,WU D D,et al. LPA induces IL-6secretion from aortic smooth muscle cells via anLPA1-regulated,PKC-dependent,and p38alphamediatedpathway[J]. Am J Physiol Heart CircPhysiol,2010,298(3):974-983.[22] GUO H,MAKAROVA N,CHENG Y,et al. Theearly- and late stages in phenotypic modulation ofvascular smooth muscle cells:differential roles forlysophosphatidic acid[J]. Biochim Biophys Acta,2008,1781(9):571-581.[23] LLODRÁ J,ANGELI V,LIU J,et al. Emigrationof monocyte-derived cells from atheroscleroticlesions characterizes regressive,but not progressive,plaques[J]. Proc Natl Acad Sci U S A,2004,101(32):11 779-11 784.[24] RAY R,RAI V. Lysophosphatidic acid convertsmonocytes into macrophages in both mice andhumans[J]. Blood,2017,129(9):1177-1183.[25] AN D,HAO F,ZHANG F,et al. CD14 is akey mediator of both lysophosphatidic acidand lipopolysaccharide induction of foam cellformation[J]. J Biol Chem,2017,292(35):14 391-14 400.[26] HOWELL K W,MENG X,FULLERTON D A,etal. Toll-like receptor 4 mediates oxidized LDLinducedmacrophage differentiation to foam cells[J/OL]. J Surg Res,2011,171(1):e27-e31. https://doi.org/10.1016/j.jss.2011.06.033.[27] YANG B,ZHOU Z,LI X,et al. The effect oflysophosphatidic acid on Toll-like receptor 4expression and the nuclear factor-κB signalingpathway in THP-1 cells[J]. Mol Cell Biochem,2016,422(1-2):41-49.[28] ZHENG H,FU Y,HUANG Y,et al. mTORsignaling promotes foam cell formation and inhibitsfoam cell egress through suppressing the SIRT1signaling pathway[J]. Mol Med Rep,2017,16(3):3315-3323.[29] YUNG Y C,STODDARD N C,CHUN J. LPAreceptor signaling:pharmacology,physiology,andpathophysiology[J]. J Lipid Res,2014,55(7):1192-1214.[30] CHEN R,ROMAN J,GUO J,et al.Lysophosphatidic acid modulates the activation ofhuman monocyte-derived dendritic cells[J]. StemCells Dev,2006,15(6):797-804.[31] BAI Z,CAI L,UMEMOTO E,et al. Constitutivelymphocyte transmigration across the basal laminaof high endothelial venules is regulated by theautotaxin/lysophosphatidic acid axis[J]. J Immunol,2013,190(5):2036-2048.[32] NAKASAKI T,TANAKA T,OKUDAIRA S,et al.Involvement of the lysophosphatidic acid-generatingenzyme autotaxin in lymphocyte-endothelial cellinteractions[J]. Am J Pathol,2008,173(5):1566-1576.[33] ROTHER E,BRANDL R,BAKER D L,et al.Subtype-selective antagonists of lysophosphatidicAcid receptors inhibit platelet activation triggeredby the lipid core of atherosclerotic plaques[J].Circulation,2003,108(6):741-747. |
[1] | LIU Yitong, HUANG Yanqi, LI Mingli, FENG Feng, GAO Shan, XU Weihai. Carotid Artery Geometry: A Potential Predictor for Intracranial Atherosclerosis in People at Age 60 or Less than 60 Years without Traditional Vascular Risk Factors [J]. Chinese Journal of Stroke, 2022, 17(09): 925-931. |
[2] | GONG Yutian, LI Jiejie. Advances in the Relationship between IL-6 and Atherosclerotic Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(09): 1022-1026. |
[3] | SONG Xinjie, WANG Anxin, LI Zixiao, ZHAO Xingquan. Relationship between Deep Vein Thrombosis of the Lower Extremity and Prognosis of Patients with IntracerebralHemorrhage [J]. Chinese Journal of Stroke, 2022, 17(06): 634-637. |
[4] | LIU Xin, PU Yuehua, YAN Zhengzheng, LIU Jia, LIU Liping. Computational Fluid Dynamics Method for Stroke Recurrence Risk Evaluation in Intracranial Artery Stenosis [J]. Chinese Journal of Stroke, 2022, 17(06): 638-642. |
[5] | WENG Jiaxu, QIU Xin, LI Zixiao. Progress of the Relationship between TET2 Mutation Related Clonal Hematopoiesis of Indeterminate Potential and Stroke [J]. Chinese Journal of Stroke, 2022, 17(04): 413-417. |
[6] | HU Jian-Gang, LIAO Wen-Kai, ZHENG Yong, SONG Jian-Xun, YE Hua-Wei, HUANG Ju-Ke. Characteristics of HR MR Vessel Wall Imaging of Culprit Artery after Recanalization in Yong and Elder Patients with Acute Middle Cerebral Artery Occlusion [J]. Chinese Journal of Stroke, 2021, 16(11): 1150-1155. |
[7] | YAN Ran, SHANGGUAN Yi, QIU Xin, LI Zi-Xiao. Mechanism of DNMT3A in Atherosclerosis [J]. Chinese Journal of Stroke, 2021, 16(11): 1178-1182. |
[8] | GAO Hao-Ran, WANG Yan, DUAN Yu-Qing, XU Shan-Shan, MIAO Ming-Yue, CHENG Kun-Ming, ZHOU Jian-Xin, ZHANG Lin-Lin. Incidence, Risk Factors and In-hospital Outcome of Venous Thromboembolism in Neurocritical Patients [J]. Chinese Journal of Stroke, 2021, 16(07): 694-698. |
[9] | XU Wei-Dong, CHEN Ru-Dong, LI Hua, ZENG Ling-Cheng, YANG Hong-Kuan, YU Jia-Sheng. Tirofiban for Periprocedural In-stent Thrombosis during Stent-assisted Coiling of Intracranial Aneurysms:A Single Center Experience#br# [J]. Chinese Journal of Stroke, 2021, 16(06): 556-560. |
[10] | ZHOU Xue-Jiao, CHEN Qing-Qing, SUN Jin-Ju, JI Rui-Jun. Analysis of Risk Factors of Lower Extremity Deep Venous Thrombosis in Patients with Subarachnoid Hemor-rhage [J]. Chinese Journal of Stroke, 2021, 16(02): 163-167. |
[11] | ZHENG Yu-Ting, XU Yu-Zhu, LIU Jun-Yan. Fluid Attenuated Inversion Recovery Vascular Hyperintensity and Acute Ischemic Stroke: Correlation with Clinical and Imaging Finding [J]. Chinese Journal of Stroke, 2021, 16(02): 168-174. |
[12] | XU Li, YUAN Dan, GONG Zhong, WANG Ying-Peng, LI Dong-Hua, WANG Hai-Peng. Headache Characteristics of Cerebral Venous Thrombosis Patients with Headache as the Sole Presentation [J]. Chinese Journal of Stroke, 2020, 15(12): 1313-1316. |
[13] | YU Yi-Jiao, LIU Li, DU Juan, LI Wei, LIN Tian,LU Dong-Xu, CAI Yi-Ling. Clinical Features and Prognosis of Capsule Warning Syndrome [J]. Chinese Journal of Stroke, 2020, 15(12): 1317-1321. |
[14] | CHEN Qing-Fang, ZHAO Shun-Ying, DONG Wen, GONG Ting, CHEN Wen-Tao, LIU Xiang-Rong. A Mouse Cerebral Ischemia Model of Distal Middle Cerebral Artery Thrombosis Induced by Ferric Chloride [J]. Chinese Journal of Stroke, 2020, 15(11): 1210-1217. |
[15] | XU Zi-Qi. Progress in Diagnosis and Treatment of Complex Intracranial Posterior Circulation Atherosclerosis Lesions [J]. Chinese Journal of Stroke, 2020, 15(10): 1123-1127. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||